| 祁钰雯,陈智伟.MYC相关靶点及其抑制剂在肿瘤靶向治疗中的研究进展[J].中国肿瘤,2024,33(1):74-79. |
| MYC相关靶点及其抑制剂在肿瘤靶向治疗中的研究进展 |
| Progress of MYC Related Targets and Corresponding Inhibitors in Targeted Therapy for Cancer |
| 投稿时间：2023-04-20 |
| DOI：10.11735/j.issn.1004-0242.2024.01.A011 |
|
 |
| 中文关键词: 髓细胞组织增生原癌基因 肿瘤发生 靶向治疗 抑制剂 联合用药 |
| 英文关键词:MYC tumorigenesis targeted therapy inhibitor concomitant drugs |
| 基金项目: |
|
| 摘要点击次数: 244 |
| 全文下载次数: 117 |
| 中文摘要: |
| 摘 要：髓细胞组织增生原癌基因（MYC）已被发现在约70%的肿瘤中存在表达失调，在肿瘤细胞生物学以及宿主免疫、肿瘤微环境等各方面发挥重要作用。目前通过直接或间接抑制MYC（包括抑制MYC转录、抑制MYC活性、抑制MYC-MAX复合物形成等）功能，从而抑制肿瘤增殖和调节肿瘤免疫。MYC抑制剂，其单药或联合既有化疗药物以及免疫抑制剂的研究已取得有效的临床前结果，部分研究现已进入临床试验阶段。全文基于MYC的结构和功能，对当前MYC相关靶点及其抑制剂在肿瘤靶向治疗中的研究进展作一综述。 |
| 英文摘要: |
| Abstract： Myelocytomatosis oncogene MYC is deregulated in around 70% of malignant tumors， which plays a crucial role in tumor cell-intrinsic biology and in host immunity and tumor microenvironment (TME). Inhibitors directly or indirectly targeting MYC (including targeting MYC transcription， MYC stabilization， and formation of MYC-MAX complex) can disturb tumor cell proliferation and restore host immunity response. These inhibitors either applied alone or in combination with chemotherapy agents or immune inhibitors have shown anti-cancer activities in preclinical testing， some of which are in clinical trials. This paper reviews the current research progress on structure and functions of MYC， its related targets and the application of its inhibitors in cancer targeted therapy. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |